Stock Option Vesting Details. Nektar Therapeutics recently announced that Jonathan Zalevsky, Chief R&D Officer, had his stock options vest on July 24, 2026. This milestone highlig …
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky
view original post